SFI
ATXS

Susquehanna Fundamental Investments’s Astria Therapeutics ATXS Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,051
Closed -$59K – 743
2025
Q1 		$59K Buy
+11,051
New +$77.3K ﹤0.01% 1039
2024
Q2 		$400K Buy
+44,000
New +$430K 0.01% 734

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Susquehanna Fundamental Investments's ATXS Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of Astria Therapeutics (ATXS) in Q2 2025, closing a stake of 11,051 shares — an estimated $59K sold.

Susquehanna Fundamental Investments first reported a position in ATXS in Q2 2024 and held it in 2 quarters. The position peaked at $400K in Q2 2024. 105 funds tracked by Wall St. Rank hold ATXS as of Q2 2025.

  • Susquehanna Fundamental Investments reported no remaining Astria Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 11,051 Astria Therapeutics shares in Q2 2025, an estimated $59K.
  • Susquehanna Fundamental Investments first reported a position in Astria Therapeutics in Q2 2024 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Astria Therapeutics position peaked at $400K in Q2 2024.
  • 105 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.